8-K: Teva Pharma Switches to Ordinary Shares on NYSE

Teva Pharmaceutical Industries Ltd. has transitioned its ordinary shares to trade directly on the New York Stock Exchange, replacing its American Depositary Shares (ADSs) program.

Summary

• Teva Pharmaceutical Industries Ltd. announced the commencement of trading for its ordinary shares on the New York Stock Exchange (NYSE) on September 14, 2026.
• The company's ordinary shares now trade under the same ticker symbol, TEVA, previously used for its American Depositary Shares (ADSs).
• The ADS program has been terminated, with each ADS being exchanged for one ordinary share.
• Teva's ordinary shares continue to be listed and traded on the Tel Aviv Stock Exchange under the symbol TEVA.
• Further details are accessible via the investor relations section of Teva's website.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, primarily reflecting a procedural change in how shares are traded rather than a fundamental shift in the company's operations or financial performance.

Positives

• Direct trading of ordinary shares on the NYSE may simplify the investment process for some shareholders.
• Maintaining the same ticker symbol (TEVA) on the NYSE minimizes confusion for investors.
• The continued listing on the Tel Aviv Stock Exchange provides ongoing access for that market.

Negatives

• The termination of the ADS program could potentially reduce liquidity for certain international investors who preferred the ADS structure.
• There is no immediate indication of improved financial performance or strategic advantage stemming directly from this change.

Risks

• Potential for initial trading volatility as the market adjusts to the new share structure.
• Any unforeseen complexities in the transition process could lead to temporary disruptions.

Future Outlook

The filing does not contain specific forward-looking statements or guidance related to financial performance. The outlook is tied to the company's ongoing business operations and market performance.

Management Comments

• The company's ordinary shares continue to trade on the Tel Aviv Stock Exchange under the same symbol, TEVA.

Industry Context

StockSavvy.ai notes that the shift from an ADS program to direct listing of ordinary shares on a major exchange like the NYSE is a structural change. While not uncommon, it can sometimes be driven by a desire to streamline operations, reduce costs associated with maintaining an ADS program, or align with investor preferences for direct share ownership.

Management Changes

Stakeholder Impact

• Shareholders: May experience changes in trading mechanics and potentially liquidity depending on their previous method of holding Teva stock.
• Investors: May find it simpler to invest directly in ordinary shares on the NYSE.
• The company: Potentially streamlines its share listing structure and associated administrative costs.

Next Steps

• Continued trading of ordinary shares on the NYSE and Tel Aviv Stock Exchange.
• Shareholders to monitor the performance of ordinary shares on the NYSE.

Key Dates

Keywords

Share trading, New York Stock Exchange, Ordinary Shares, ADS termination, Tel Aviv Stock Exchange, Teva Pharmaceutical Industries